The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs

Cancer Treatment Reviews

Volumn 33, Issue 5, 2007, Pages 448-460

  Logan, Richard M ^a,b   Stringer, Andrea M ^c,d   Bowen, Joanne M ^c,d   Yeoh, Ann S J ^c,d   Gibson, Rachel J ^c,d   Sonis, Stephen T ^e   Keefe, Dorothy M K ^c,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Animal models; Chemotherapy; Mucositis; NF B; Pro inflammatory cytokines

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ATROPINE; CISPLATIN; CLARITHROMYCIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRINOTECAN; MELPHALAN; METHOTREXATE; PALIFERMIN; PENTOXIFYLLINE; PROTEGRIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELAFERMIN;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLOATING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CYTOKINE PRODUCTION; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DRUG RECEPTOR BINDING; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; INFLAMMATORY DISEASE; IONIZING RADIATION; MALIGNANT NEOPLASTIC DISEASE; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PAIN; PROTEIN SYNTHESIS INHIBITION; REVIEW; SMALL INTESTINE DISEASE;

EID: 34548230499     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.03.001     Document Type: Review

References (131)

1. Keefe D.M.K. Gastrointestinal mucositis: a new biological model. Support Care Cancer 12 (2004) 6-9
2. Peterson D., Keefe D.M., Hutchins R., and Schubert M. Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice. Supportive Care in Cancer 14 6 (2006) 499-504
3. Keefe D.M.K., Brealey J., Goland G.J., and Cummins A.G. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 47 5 (2000) 632-637
4. Pico J.-L., Avila-Garavito A., and Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. The Oncologist 3 (1998) 446-451
5. Keefe D.M., and Gibson R.J. Mucosal injury from targeted anti-cancer therapy. Supportive Care Cancer 15 5 (2007) 483-490
6. Bellm L.A., Epstein J.B., Rose-Ped A., Martin P., and Fuchs H.J. Patient reports of complications of bone marrow transplantation. Support Care Cancer 8 1 (2000) 33-39
7. Parulekar W., Mackenzie R., Bjarnason G., and Jordan R.C.K. Scoring oral mucositis. Oral Oncol 34 (1998) 63-71
8. Elting L.S., Cooksley C., Chambers M.S., et al. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98 (2003) 1531-1539
9. Montejo J.C. Enteral nutrition-related gastrointestinal complications in critically ill patients: a multicenter study. The Nutritional and Metabolic Working Group of the Spanish Society of Intensive Care Medicine and Coronary Units. Crit Care Med 27 8 (1999) 1447-1453
10. Rubenstein E.B., Peterson D., Schubert M., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100 S9 (2004) 2026-2046
11. Sonis S.T. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34 1 (1998) 39-43
12. Scully C., Epstein J., and Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck 25 12 (2003) 1057-1070
13. Yeoh A., Gibson R., Yeoh E., et al. Radiation therapy-induced mucositis: relationships between fractionated radiation, NF-κB, COX-1, and COX-2. Cancer Treatment Rev 32 8 (2006) 645-651
14. Spijkervet F.K., Van Saene H.K., Van Saene J.J., et al. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol 46 3 (1991) 167-173
15. Stiff P. Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant 27 Suppl 2 (2001) S3-S11
16. Sonis S.T., Tracey C., Shklar G., Jenson J., and Florine D. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 69 4 (1990) 437-443
17. Menendez J.C., Casanova D., Amado J.A., et al. Effects of radiation on endothelial function. Int J Radiat Oncol*Biol*Phys 41 4 (1998) 905-913
18. Maj J.G., Paris F., Haimovitz-Friedman A., et al. Microvascular function regulates intestinal crypt response to radiation. Cancer Res 63 15 (2003) 4338-4341
19. Paris F., Fuks Z., Kang A., et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293 5528 (2001) 293-297
20. Garcia-Barros M., Paris F., Cordon-Cardo C., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 5622 (2003) 1155-1159
21. Sonis S.T., Peterson R.L., Edwards L.J., et al. Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36 4 (2000) 373-381
22. Sonis S.T., Elting L.S., Keefe D., et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100 9 Suppl (2004) 1995-2025
23. Sonis S.T. The pathobiology of mucositis. Nat Rev Cancer 4 4 (2004) 277-284
24. Sonis S.T. The biologic role for nuclear factor-κB in disease and its potential involvement in mucosal injury associated with antineoplastic therapy. Crit Rev Oral Biol Med 13 5 (2002) 380-390
25. Hall P.D., Benko H., Hogan K.R., and Stuart R.K. The influence of serum tumor necrosis factor-α and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol 23 12 (1995) 1256-1260
26. Ferra C., de Sanjose S., Gallardo D., et al. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Haematologica 83 12 (1998) 1082-1087
27. Tadashi Y. Cartilage destruction by matrix degradation products. Modern Rheumatol V16 4 (2006) 197-205
28. Gibson R.J., Cummins A.G., Bowen J.M., et al. Apoptosis occurs early in the basal layer of the oral mucosa following cancer chemotherapy. Asian Pacific J Clin Oncol 2 (2006) 39-49
29. Logan R.M., Gibson R.J., Sonis S.T., and Keefe D.M.K. Nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43 4 (2007) 395-401
30. Anthony L., Bowen J., Garden A., Hewson I., and Sonis S. New thoughts on the pathobiology of regimen-related mucosal injury. Supportive Care Cancer (2006) 1-3
31. Dinarello C.A. Proinflammatory cytokines. Chest 118 2 (2000) 503-508
32. Sonis S.T., Costa Jr. J.W., Evitts S.M., Lindquist L.E., and Nicolson M. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol 74 6 (1992) 749-755
33. Sonis S.T., Van Vugt A.G., Brien J.P., et al. Transforming growth factor-β3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncol 33 1 (1997) 47-54
34. Antin J., and Ferrara J. Cytokine dysregulation and acute graft-versus-host disease. Blood 80 12 (1992) 2964-2968
35. Spielberger R., Stiff P., Bensinger W., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351 25 (2004) 2590-2598
36. Potting C.M.J., Blijlevens N.A.M., Donnelly J.P., Feuth T., and Van Achterberg T. A scoring system for the assessment of oral mucositis in daily nursing practice. Eur J Cancer Care 15 3 (2006) 228-234
37. Ghosh S., and Karin M. Missing pieces in the NF-[κ]B puzzle. Cell 109 2, Suppl. 1 (2002) S81-S96
38. Hanada T., and Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 13 4-5 (2002) 413-421
39. Loury D., Embree J.R., Steinberg D.A., Sonis S.T., and Fiddes J.C. Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 87 5 (1999) 544-551
40. Biswas D.K., Martin K.J., McAlister C., et al. Apoptosis caused by chemotherapeutic inhibition of nuclear factor-{κ}B activation. Cancer Res 63 2 (2003) 290-295
41. Bowen J.M., Gibson R.J., Keefe D.M., and Cummins A.G. Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 37 1 (2005) 56-62
42. Strasser A., O'Connor L., and Dixit V.M. Apoptosis signalling. Annu Rev Biochem 69 1 (2000) 217-245
43. Carswell E.A., Old L.J., Kassel R.L., et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72 9 (1975) 3666-3670
44. Hehlgans T., and Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115 1 (2005) 1-20
45. Lorenz H.-M., and Kalden J.R. Perspectives for TNF-α-targeting therapies. Arthritis Res 4 Suppl 3 (2002) S17-S24
46. Mocellin S., Rossi C.R., Pilati P., and Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 16 1 (2005) 35-53
47. Holler E., Kolb H., Moller A., et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75 4 (1990) 1011-1016
48. Bianco J.A., Appelbaum F.R., Nemunaitis J., et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 78 5 (1991) 1205-1211
49. Sleijfer S., Vujaskovic Z., Limburg P.C., Koops H.S., and Mulder N.H. Induction of tumor necrosis factor-α as a cause of bleomycin-related toxicity. Cancer 82 5 (1998) 970-974
50. Rabinowitz J., Petros W., Stuart A., and Peters W. Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support. Blood 81 9 (1993) 2452-2459
51. Ferra C., de Sanjose S., Lastra C.F., et al. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications. Bone Marrow Transplant 20 12 (1997) 1075-1080
52. Lima V., Brito G.A.C., Cunha F.Q., et al. Effects of the tumour necrosis factor-α inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. Eur J Oral Sci 113 3 (2005) 210-217
53. Orlicek S.L., Branum K.C., English B.K., et al. Viridans streptococcal isolates from patients with septic shock induce tumor necrosis factor-α production by murine macrophages. J Lab Clin Med 130 5 (1997) 515-519
54. Dinarello C. Biologic basis for interleukin-1 in disease. Blood 87 6 (1996) 2095-2147
55. Blijlevens N., and Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol (2006) mdl332
56. Nishimoto N., and Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 4 4 (2004) 386-391
57. Taupin D., and Podolsky D.K. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 4 9 (2003) 721-732
58. Naka T., Nishimoto N., and Kishimoto K. The paradigm of IL-6: from basic science to medicine. Arthritis Res 4 Suppl 3 (2002) S233-S242
59. Kishimoto T., Akira S., Narazaki M., and Taga T. Interleukin-6 family of cytokines and gp130. Blood 86 4 (1995) 1243-1254
60. Moller B., and Villiger P. Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases. Springer Semin Immunopathol V27 4 (2006) 391-408
61. Wang L., Walia B., Evans J., et al. IL-6 Induces NF-{κ}B activation in the intestinal epithelia. J Immunol 171 6 (2003) 3194-3201
62. Sonis S., Koplowsky A., Mitus J., Rosenthal D., and Brand M. Relationship of chemotherapy-induced mucositis and myelosuppression in hamsters. Eur J Cancer B Oral Oncol 28B 1 (1992) 43
63. Keith Jr. J.C., Albert L., Sonis S.T., Pfeiffer C.J., and Schaub R.G. IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells 12 Suppl 1 (1994) 79-89 Discussion 89-90
64. Sonis S.T., Lindquist L., Van Vugt A., et al. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3. Cancer Res 54 5 (1994) 1135-1138
65. Sonis S., Muska A., O'Brien J., et al. Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Eur J Cancer B Oral Oncol 31B 4 (1995) 261-266
66. Sonis S.T., Van Vugt A.G., McDonald J., et al. Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters. Cytokine 9 8 (1997) 605-612
67. Clarke J., Edwards B., Srpek L., and Regester G. Evaluation of bovine lactoferrin as a topical therapy for chemotherapy-induced mucositis in the golden Syrian hamster. Oral Oncology 35 2 (1999) 197-202
68. Sonis S.T., O'Donnell K.E., Popat R., et al. The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 40 2 (2004) 170-176
69. Alvarez E., Fey E.G., Valax P., et al. Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clin Cancer Res 9 9 (2003) 3454-3461
70. Morvan F.O., Baroukh B., Ledoux D., et al. An engineered biopolymer prevents mucositis induced by 5-fluorouracil in hamsters. Am J Pathol 164 2 (2004) 739-746
71. Aksungur P., Sungur A., Unal S., et al. Chitosan delivery systems for the treatment of oral mucositis: in vitro and in vivo studies. J Controlled Release 98 2 (2004) 269-279
72. Mitsuhashi H., Suemaru K., Li B., and Araki H. Evaulation of topical external medicine for 5-fluorouracil-induced oral mucositis in hamsters. Eur J Pharmacol 551 1-3 (2006) 152-155
73. Cho S.-A., Park J.-H., Seok S.-H., et al. Effect of granulocyte macrophage-colony stimulating factor (GM-CSF) on 5-FU-induced ulcerative mucositis in hamster buccal pouches. Exp Toxicol Pathol 57 4 (2006) 321-328
74. Clarke J., Butler R., Howarth G., Read L., and Regester G. Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster. Oral Oncol 38 5 (2002) 478-485
75. Epstein J.B., Emerton S., Guglietta A., and Le N. Assessment of epidermal growth factor in oral secretions of patients receiving radiation therapy for cancer. Oral Oncol 33 5 (1997) 359-363
76. Leitão R.F.C., Ribeiro R.A., Bellaguarda E.A.L., et al. Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. Cancer Chemother Pharmacol 59 5 (2007) 603-612
77. Barasch A., Elad S., Altman A., Damato K., and Epstein J. Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Supportive Care Cancer 14 6 (2006) 528-532
78. Chen J., Falla T.J., Liu H., et al. Development of protegrins for the treatment and prevention of oral mucositis: Structure-activity relationships of synthetic protegrin analogues. Peptide Sci 55 1 (2000) 88-98
79. Borges L., Rex K.L., Chen J.N., et al. A protective role for keratinocyte growth factor in a murine model of chemotherapy and radiotherapy-induced mucositis. Int J Radiat Oncol Biol Phys 66 1 (2006) 254-262
80. Dorr W., Bassler S., Reichel S., and Spekl K. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice. Int J Radiat Oncol Biol Phys 62 3 (2005) 881-887
81. Huang F.S., Kemp C.J., Williams J.L., Erwin C.R., and Warner B.W. Role of epidermal growth factor and its receptor in chemotherapy-induced intestinal injury. Am J Physiol Gastrointest Liver Physiol 282 3 (2002) G432-G442
82. Farrell C.L., Bready J.V., Rex K.L., et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 58 5 (1998) 933-939
83. Ramos M.G., Bambirra E.A., Cara D.C., Vieira E.C., and Alvarez-Leite J.I. Oral administration of short-chain fatty acids reduces the intestinal mucositis caused by treatment with Ara-C in mice fed commercial or elemental diets. Nutr Cancer 28 2 (1997) 212-217
84. Morelli D., Menard S., Colnaghi M.I., and Balsari A. Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res 56 9 (1996) 2082-2085
85. Balsari A., Rumio C., Morelli D., et al. Topical administration of a doxorubicin-specific monoclonal antibody prevents drug-induced mouth apoptosis in mice. Br J Cancer 85 12 (2001) 1964-1967
86. Dorr W., Heider K., and Spekl K. Reduction of oral mucositis by palifermin (rHuKGF): dose-effect of rHuKGF. Int J Radiat Biol 81 8 (2005) 557-565
87. Kang S.-J., Popat R., Bragdon C., et al. Caspase-11 is not necessary for chemotherapy-induced intestinal mucositis. DNA Cell Biol 23 8 (2004) 490-495
88. de Koning B.A., Sluis M., Lindenbergh-Kortleve D.J., et al. Methotrexate-induced mucositis in mucin 2-deficient mice. J Cell Physiol 210 1 (2007) 144-152
89. Beck P.L., Wong J.F., Li Y., et al. Chemotherapy- and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology 126 3 (2004) 796-808
90. Woo P.C.Y., Ng W.F., Leung H.C.H., Tsoi H.W., and Yuen K.Y. Clarithromycin attenuates cyclophosphamide-induced mucositis in mice. Pharmacol Res 41 5 (2000) 527-532
91. Sun Z., Wang X., Wallen R., et al. The influence of apoptosis on intestinal barrier integrity in rats. Scand J Gastroenterol 33 4 (1998) 415-422
92. Dorr W., Spekl K., and Farrell C.L. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol*Biol*Phys 54 1 (2002) 245-251
93. Dorr W., Spekl K., and Farrell C.L. The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. Cell Prolif 35 s1 (2002) 86-92
94. Dorr W., Noack R., Spekl K., and Farrell C.L. Modification of oral mucositis by keratinocyte growth factor: single radiation exposure. Int J Radiat Biol 77 3 (2001) 341-347
95. Potten C.S., O'Shea J.A., Farrell C.L., Rex K., and Booth C. The effects of repeated doses of keratinocyte growth factor on cell proliferation in the cellular hierarchy of the crypts of the murine small intestine. Cell Growth Differ 12 5 (2001) 265-275
96. Dorr W., Bassler S., Reichel S., and Spekl K. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice. Int J Radiat Oncol*Biol*Phys 62 3 (2005) 881-887
97. Kang S.-J., Wang S., Hara H., et al. Dual role of caspase-11 in mediating activation of caspase-1 and caspase-3 under pathological conditions. J Cell Biol 149 3 (2000) 613-622
98. Gibson R.J., Bowen J.M., Inglis M.R.B., Cummins A.G., and Keefe D.M.K. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 18 9 (2003) 1095-1100
99. Bowen J.M., Gibson J., Cummins A.G., Tyskin A., and Keefe D.M. Irinotecan changes gene expression in the small intestine of the rat with breast cancer. Cancer Chemother Pharmacol V59 3 (2007) 337-348
100. Logan R.M., Gibson R.J., Sonis S.T., and Keefe D.M.K. Nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43 4 (2007) 395-401
101. Gibson R.J., Bowen J.M., and Keefe D.M. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 116 3 (2005) 464-470
102. Cool J.C., Dyer J.L., Xian C.J., et al. Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Hormone IGF Res 15 1 (2005) 72-82
103. Howarth G.S., Francis G.L., Cool J.C., et al. Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 126 10 (1996) 2519-2530
104. Tran C.D., Howarth G., Coyle P., et al. Dietary supplementation with zinc and a growth factor extract derived from bovine cheese whey improves methotrexate-damaged rat intestine. Am J Clin Nutr 77 (2003) 1296-1303
105. Gibson R.J., Keefe D.M., Clarke J., et al. The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 50 1 (2002) 53-58
106. Howarth G.S., Tooley K.L., Davidson G.P., and Butler R.N. A non-invasive method for detection of intestinal mucositis induced by different classes of chemotherapy drugs in the rat. Cancer Biol Ther 5 9 (2006) 1189-1195
107. Clarke J.M., Pelton N.C., Bajka B.H., et al. Use of the 13C-sucrose breath test to assess chemotherapy-induced small intestinal mucositis in the rat. Cancer Biol Ther 5 1 (2006) 34-38
108. Gibson R.J., Keefe D.M., Thompson F.M., et al. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47 12 (2002) 2751-2757
109. Gibson R., and Keefe D. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Supportive Care Cancer (2006) 1-11
110. Alimonti A., Gelibter A., Pavese I., et al. New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treatment Rev 30 6 (2004) 555-562
111. Kawahara M. Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations. Expert Opin Drug Safety 5 2 (2006) 303-312
112. Keefe D.M., Gibson R.J., and Hauer-Jensen M. Gastrointestinal mucositis. Semin Oncol Nurs 20 1 (2004) 38-47
113. Takasuna K., Hagiwara T., Watanabe K., et al. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea. Cancer Chemother Pharmacol V58 4 (2006) 494-503
114. Goto S., Okutomi T., Suma Y., et al. Induction of tumor necrosis factor by a camptothecin derivative, irinotecan, in mice and human mononuclear cells. Anticancer Res 16 5A (1996) 2507-2511
115. Xu Y., and Villalona-Calero M.A. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13 12 (2002) 1841-1851
116. Carneiro-Filho B.A., Lima I.P., Araujo D.H., et al. Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis. Dig Dis Sci 49 1 (2004) 65-72
117. Majumdar S., and Aggarwal B.B. Methotrexate suppresses NF-{κ}B activation through inhibition of I{κ}B{α} phosphorylation and degradation. J Immunol 167 5 (2001) 2911-2920
118. Kremer J.M. Toward a better understanding of methotrexate. Arthritis Rheum 50 5 (2004) 1370-1382
119. Gibson R.J., Bowen J.M., Cummins A.G., and Keefe D.M.K. Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clin Exp Med 4 4 (2005) 188-195
120. de Koning B.A.E., van Dieren J.M., Lindenbergh-Kortleve D.J., et al. Contributions of mucosal immune cells to methotrexate-induced mucositis. Int Immunol 18 6 (2006) 941-949
121. Azuma M., Yamashita T., Aota K., Tamatani T., and Sato M. 5-Fluorouracil suppression of NF-[κ]B is mediated by the inhibition of I[κ]B kinase activity in human salivary gland cancer cells. Biochem Biophys Res Commun 282 1 (2001) 292-296
122. Aota K., Azuma M., Yamashita T., et al. 5-Fluorouracil induces apoptosis through the suppression of NF-[κ]B activity in human salivary gland cancer cells. Biochem Biophys Res Commun 273 3 (2000) 1168-1174
123. Pritchard D.M., Jackman A., Potten C.S., and Hickman J.A. Chemically-induced apoptosis: p21 and p53 as determinants of enterotoxin activity. Toxicol Lett 102-103 (1998) 19-27
124. Li C.-Q., and Wogan G.N. Nitric oxide as a modulator of apoptosis. Cancer Lett 226 1 (2005) 1-15
125. Rapidis A.D., Trichas M., Stavrinidis E., et al. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: Final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. Oral Oncol 42 7 (2006) 675-684
126. Lam L., Logan R.M., Luke C., and Rees G.L. Retrospective study of survival and treatment pattern in a cohort of patients with oral and oropharyngeal tongue cancers from 1987 to 2004. Oral Oncol 43 2 (2007) 150-158
127. Hanna E., Alexiou M., Morgan J., et al. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations. Arch Otolaryngol Head Neck Surg 130 7 (2004) 861-867
128. Woo S., Sonis S.T., Monopoli M., and Sonis A. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 72 5 (1993) 1612-1617
129. Iguchi H., Kusuki M., Nakamura A., et al. Outcome of preoperative concurrent chemoradiotherapy and surgery for resectable lingual squamous cell carcinoma greater than 3 cm: the possibility of less extensive surgery. Oral Oncol 42 4 (2006) 391-397
130. Altundag O., Gullu I., Altundag K., et al. Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients. Head Neck 27 1 (2005) 15-21
131. Franchin G., Vaccher E., Gobitti C., et al. Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma. Oral Oncol 41 5 (2005) 526-533